Following the pack, Immunovant rushes into pivotal studies

Validation of the anti-FcRn mechanism by more advanced rivals seems to have been partly behind Immunovant’s bold decision to halt enrolment in its phase I myasthenia gravis trial of IMVT-1401 at a mere 15 patients. Keenly awaited results from the Ascend MG trial presented yesterday certainly look competitive, although the very small patient number is hard to ignore.